Table 1. Summary of selected studies of MPM patient undergoing CRS and HIPEC.
| Author, year | Study type | N | Median OS, months | 5-year survival, % |
|---|---|---|---|---|
| Yan, 2009 | Multi-institution, international | 405 | 53 | 47 |
| Alexander, 2013 | Multi-institution, United States review | 211 | 38 | 41 |
| Helm, 2015 | Meta-analysis of 20 CRS-HIPEC publications | 1,047 | NA | 42 |
| Miura, 2014 | SEER database | 1,591 | 38 | NA |
| Li, 2017 | Single institution | 100 | 33 | 36 |
CRS-HIPEC demonstrates median OS approaching 5 years in some studies. MPM, malignant peritoneal mesothelioma; CRS-HIPEC, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; OS, overall survival; NA, not applicable.